辅助曲妥珠单抗：时间真的重要吗？
Adjuvant trastuzumab: does time really matter?
机构信息
Washington Cancer Institute, MedStar Washington Hospital Center, Washington, District of Columbia 20010, USA.
出版信息
Oncologist. 2013;18(5):490-2. doi: 10.1634/theoncologist.2013-0094. Epub 2013 Apr 26.
Abstract
Trastuzumab is now the standard of care for metastatic and early breast cancer; however, questions remain regarding the optimal schedule of trastuzumab in the adjuvant setting. This commentary discusses the results from recent clinical trials with regard to the optimal duration of trastuzumab treatment, as well as the benefits of providing trastuzumab sequentially versus concurrently to chemotherapy.
摘要
曲妥珠单抗现已成为转移性和早期乳腺癌的标准治疗方法；然而，在辅助治疗环境中，曲妥珠单抗的最佳方案仍存在疑问。本评论讨论了最近临床试验中关于曲妥珠单抗治疗最佳持续时间的结果，以及与化疗序贯或同时使用曲妥珠单抗的益处。
相似文献
1
Adjuvant trastuzumab: does time really matter?辅助曲妥珠单抗：时间真的重要吗？
Oncologist. 2013;18(5):490-2. doi: 10.1634/theoncologist.2013-0094. Epub 2013 Apr 26.
2
Monoclonal antibody therapy for breast cancer: herceptin.乳腺癌的单克隆抗体疗法：赫赛汀
Cancer Chemother Biol Response Modif. 2003;21:223-33. doi: 10.1016/s0921-4410(03)21010-3.
3
Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.曲妥珠单抗治疗人表皮生长因子受体 2 阳性乳腺癌：给药途径、疗程和联合治疗方案。
Breast. 2013 Aug;22 Suppl 2:S152-5. doi: 10.1016/j.breast.2013.07.029.
4
Spotlight on trastuzumab as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.曲妥珠单抗作为人表皮生长因子受体2（HER2）阳性早期乳腺癌辅助治疗的聚焦
BioDrugs. 2010 Jun;24(3):207-9. doi: 10.2165/11204680-000000000-00000.
5
CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).曲妥珠单抗辅助治疗 HER2 阳性早期乳腺癌患者中枢神经系统复发情况：HERA 试验（BIG 1-01）的回顾性亚组研究
Lancet Oncol. 2013 Mar;14(3):244-8. doi: 10.1016/S1470-2045(13)70017-2. Epub 2013 Feb 13.
6
Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines?选择最佳的基于曲妥珠单抗的辅助化疗方案：我们应该摒弃蒽环类药物吗？
J Clin Oncol. 2012 Jun 20;30(18):2179-82. doi: 10.1200/JCO.2012.42.0695. Epub 2012 May 21.
7
Pertuzumab (Perjecta) for HER2-positive metastatic breast cancer.帕妥珠单抗（帕捷特）用于治疗HER2阳性转移性乳腺癌。
Med Lett Drugs Ther. 2012 Jul 23;54(1395):59-60.
8
Is the Preoperative Setting an Appropriate Platform for Drug Approval in Breast Cancer?术前阶段是否是乳腺癌药物审批的合适平台？
J Natl Compr Canc Netw. 2015 Nov;13(11):1448-52. doi: 10.6004/jnccn.2015.0169.
9
"Build quality in"--HER2 testing in the real world.将质量融入其中——现实世界中的HER2检测
J Natl Cancer Inst. 2002 Jun 5;94(11):788-9. doi: 10.1093/jnci/94.11.788.
10
Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer.辅助曲妥珠单抗联合化疗对小的、淋巴结阴性、HER2 阳性乳腺癌女性有效。
Cancer. 2011 Dec 15;117(24):5461-8. doi: 10.1002/cncr.26171. Epub 2011 Jun 16.
引用本文的文献
1
Cardiotoxicity Assessment After Different Adjuvant Hypofractionated Radiotherapy Concurrently Associated with Trastuzumab in Early Breast Cancer.早期乳腺癌中不同辅助性短程放疗与曲妥珠单抗联合应用后的心脏毒性评估
In Vivo. 2018 Jul-Aug;32(4):879-882. doi: 10.21873/invivo.11322.
本文引用的文献
1
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.曲妥珠单抗联合辅助化疗用于人表皮生长因子受体2阳性乳腺癌：NSABP B-31和NCCTG N9831总生存的计划联合分析
J Clin Oncol. 2014 Nov 20;32(33):3744-52. doi: 10.1200/JCO.2014.55.5730. Epub 2014 Oct 20.
2
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.多中心 II 期研究：曲妥珠单抗和拉帕替尼联合激素治疗且不联合化疗治疗人表皮生长因子受体 2 过表达乳腺癌患者：TBCRC 006。
J Clin Oncol. 2013 May 10;31(14):1726-31. doi: 10.1200/JCO.2012.44.8027. Epub 2013 Apr 8.
3
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.NSABP B-31 试验的 7 年心脏功能随访评估，该试验为随机试验，比较了多柔比星和环磷酰胺序贯紫杉醇（ACP）与 ACP 联合曲妥珠单抗用于治疗人表皮生长因子受体 2 阳性、淋巴结阳性乳腺癌患者的辅助治疗。
J Clin Oncol. 2012 Nov 1;30(31):3792-9. doi: 10.1200/JCO.2011.40.0010. Epub 2012 Sep 17.
4
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.新辅助帕妥珠单抗和曲妥珠单抗治疗局部晚期、炎症型或早期 HER2 阳性乳腺癌的疗效和安全性（NeoSphere）：一项随机、多中心、开放性、Ⅱ期临床试验。
Lancet Oncol. 2012 Jan;13(1):25-32. doi: 10.1016/S1470-2045(11)70336-9. Epub 2011 Dec 6.
5
Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer.曲妥珠单抗辅助化疗序贯与联合治疗乳腺癌的比较。
J Clin Oncol. 2011 Dec 1;29(34):4491-7. doi: 10.1200/JCO.2011.36.7045. Epub 2011 Oct 31.
6
Adjuvant trastuzumab in HER2-positive breast cancer.曲妥珠单抗辅助治疗 HER2 阳性乳腺癌。
N Engl J Med. 2011 Oct 6;365(14):1273-83. doi: 10.1056/NEJMoa0910383.
7
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.曲妥珠单抗联合辅助化疗治疗可手术的人表皮生长因子受体 2 阳性乳腺癌的 4 年随访：NCCTG N9831 和 NSABP B-31 数据的联合分析。
J Clin Oncol. 2011 Sep 1;29(25):3366-73. doi: 10.1200/JCO.2011.35.0868. Epub 2011 Jul 18.
8
Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.曲妥珠单抗在腋窝淋巴结阳性乳腺癌患者中的应用：FNCLCC-PACS 04 试验的结果。
J Clin Oncol. 2009 Dec 20;27(36):6129-34. doi: 10.1200/JCO.2009.23.0946. Epub 2009 Nov 16.
9
Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.氟尿嘧啶、表柔比星和环磷酰胺联合多西他赛或长春瑞滨，联合或不联合曲妥珠单抗，作为乳腺癌辅助治疗：芬兰乳腺癌试验（FinHer Trial）的最终结果
J Clin Oncol. 2009 Dec 1;27(34):5685-92. doi: 10.1200/JCO.2008.21.4577. Epub 2009 Nov 2.
10
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer.辅助多西他赛或长春瑞滨联合或不联合曲妥珠单抗用于乳腺癌治疗。
N Engl J Med. 2006 Feb 23;354(8):809-20. doi: 10.1056/NEJMoa053028.
Zotero 插件